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Abstract
Adrenergic receptor β2 (ADRB2) is a primary target for epinephrine. It plays a critical role in
mediating physiological and psychological responses to environmental stressors. Thus, functional
genetic variants of ADRB2 will be associated with a complex array of psychological and
physiological phenotypes. These genetic variants should also interact with environmental factors
such as physical or emotional stress to produce a phenotype vulnerable to pathological states. In
this study, we determined whether common genetic variants of ADRB2 contribute to the
development of a common chronic pain condition that is associated with increased levels of
psychological distress and low blood pressure, factors which are strongly influenced by the
adrenergic system. We genotyped 202 female subjects and examined the relationships between
three major ADRB2 haplotypes and psychological factors, resting blood pressure, and the risk of
developing a chronic musculoskeletal pain condition - Temporomandibular Joint Disorder (TMD).
We propose that the first haplotype codes for lower levels of ADRB2 expression, the second
haplotype codes for higher ADRB2 expression, and the third haplotype codes for higher receptor
expression and rapid agonist-induced internalization. Individuals who carried one haplotype
coding for high and one coding for low ADRB2 expression displayed the highest positive
psychological traits, had higher levels of resting arterial pressure, and were about 10 times less
likely to develop TMD. Thus, our data suggest that either positive or negative imbalances in
ADRB2 function increase the vulnerability to chronic pain conditions such as TMD through
different etiological pathways that imply the need for tailored treatment options.
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Introduction
Persistent pain is an unpleasant sensory and emotional experience that is associated with
several chronic disease processes and clinical conditions. One very common chronic
musculoskeletal pain condition that results from maladaptive biological and psychological
factors is myogenous temporomandibular disorder (TMD), which is characterized by
persistent facial pain, impaired oral function, and several comordid medical conditions
(NIH, National Ambulatory Medical Care Survey, 1979;John, Miglioretti et al., 2003;Von
Korff et al., 1993). In the United States, this condition impacts 5 to 15% of the adult
population and incurs ∼ $1B annually in healthcare costs (NIH, National Ambulatory
Medical Care Survey, 1979). Risk determinants for TMD include biological factors that
contribute to increases in pain sensitivity (Fillingim, Fillingim et al., 1998; Maixner,
Fillingim et al., 1995;Maixner, Sigurdsson et al., 1995;Harkins et al., 1989;Sarlani et al.,
2004) as well as psychological factors which contribute to high levels of somatization,
depression and anxiety (Ohrbach and Dworkin, 1998;Okeson et al., 1996;Epker et al.,
1999;Epker and Gatchel, 2000;Dworkin et al., 1990;Carlson et al., 1993;Keefe and Dolan,
1986;Vassend et al., 1995;Yap et al., 2003).
The profile of risk factors for TMD is consistent with the view that impairments in CNS
regulatory processes contribute to the enhanced pain sensitivity and psychological
dysfunction commonly seen in TMD patients (Fillingim, Fillingim et al 1998;Maixner,
Fillingim, Booker, and Sigurdsson, 1995;Maixner, Sigurdsson et al., 1995;Harkins et al.,
1989;Sarlani et al., 2004). We have proposed that genetic polymorphisms which influence
adrenergic receptor mediated responses, when coupled with environmental factors such as
physical or emotional stress, can produce a clinical phenotype that is vulnerable to TMD and
related comorbid conditions (Diatchenko et al., 2005). Our recent studies have shown that
genetic variations in catechol-O-methyltransferase (COMT), an enzyme that metabolizes
catecholamines and catechol substances such as catecholestrogen, substantially influences
pain perception and the risk of developing TMD (Diatchenko et al., 2005). Women who
possessed COMT haplotypes that code for low levels of COMT activity show enhanced
sensitivity to experimental pain and were 2.3 times more likely to develop TMD when
compared to women who have COMT haplotypes coding for high levels of COMT activity
(Diatchenko et al., 2005). COMT haplotypes were not found to be associated with the
psychological factors that predicted TMD onset, suggesting that there are unidentified
genetic variations which influence pain related psychological factors.
One possible candidate gene that might influence the psychological factors which contribute
to TMD risk is the gene that codes for β2-adrenergic receptor. Alterations in β-adrenergic
receptor function have been implicated in several psychiatric diseases and psychological
disorders - including those associated with chronic pain conditions. Reductions in the
density of β-adrenergic receptors are associated with depression and panic-anxiety
(Magliozzi et al., 1989). Panic disorder, with agoraphobia, is associated with decreased
lymphocyte β-adrenergic receptor density and diminished stimulation-evoked cAMP
production (Maddock et al., 1993). β-adrenergic desensitization is correlated with the
severity of psychomotor agitation seen in depressed patients (Mann et al., 1985) and the
density of ADRB2 is negatively correlated with anxiety, depression, and hostility assessed
with Profile of Mood States (POMS) questionnaire (Yu et al., 1999). Recent studies have
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also shown that the stimulation of central ADRB2 produces anti-depressive effects in
rodents (Zhang et al., 2003). In rats, central administration of the non-selective β-adrenergic
receptor agonist isoproterenol produces a dose-dependent increase in defensive withdrawal,
supporting the involvement of CNS β-adrenergic receptors in stress-related behavioral
changes (Gorman and Dunn, 1993).
ADRB2 activity also regulates resting arterial blood pressure (Small et al., 2003), which is
related to human pain sensitivity and central nervous system pain regulatory systems. In
general, higher levels of resting arterial blood pressure are associated with diminished
sensitivity to noxious thermal, mechanical, and ischemic stimuli (Bruehl and Chung,
2004;Fillingim, Maixner et al., 1998;Fillingim and Maixner, 1996;Maixner et al.,
1997;Pfleeger et al., 1997;Maixner, 1991;Randich and Maixner, 1984;Sheps et al., 1992).
Recently it has been shown that individuals with higher resting arterial pressure have a
lower prevalence of chronic musculoskeletal pain complaints (Hagen et al., 2005).
Taking into account the central role of ADRB2 in epinephrine mediated responses, we
hypothesize that functional genetic variants of ADRB2 will be associated with a complex
array of psychological and physiological phenotypes. Because specific psychological and
physiological signs and symptoms (i.e., phenotypes) are associated with and predict TMD
development, we hypothesized that certain genetic polymorphisms in ADRB2 will contribute
to the risk of developing TMD. Based on our findings, and the current knowledge related to
ADRB2 cell biology, physiology, pharmacology and molecular genetics, we have developed
a heuristic model that depicts the putative properties of the receptor physiology
corresponding to the three common haplotypes examined in this study. Our model
conceptually explains the relationship between the three ADRB2 haplotypes with resting
blood pressure, measures of psychological distress, and the risk of TMD development.
Materials and Methods
Subject recruitment
Data for this study were collected from 210 healthy female Caucasians aged 18 to 34 years
who participated in an prospective study examining risk factors for TMD (Diatchenko et al.,
2005). Only females were included in this study as they exhibit a higher prevalence of TMD
than males (Carlsson and Le Resche, 1995). At the time of recruitment, subjects completed a
baseline assessment comprised of psychological questionnaires, resting arterial blood
pressure, and a clinical examination of the head and neck. Blood samples were collected and
used for the genotyping of 8 single nucleotide polymorphisms of the ADRB2 gene. Subjects
were subsequently followed for up to 3 years, by both quarterly interviews and annual
physical examinations, to identify newly developed cases of TMD. The study received
ethical and safety approval from the University of North Carolina at Chapel Hill's
Institutional Review Board.
Psychological questionnaires
Four psychological questionnaires that assessed depression, anxiety and somatization, which
represent three major psychological domains that are consistently associated with chronic
pain conditions, were completed by the participants. The questionnaires were not used to
provide diagnoses of a psychiatric condition and we did not endeavor to make such
diagnoses in this study. The following questionnaires were used: The Profile of Mood
States- Bi-Polar (POMS-Bi) consists of 72 mood-related items that assess both positive and
negative affective dimensions (Lorr and McNair, 1988). This instrument provides measures
of mood over the previous week in six categories: agreeable-hostile, elated-depressed,
confident-unsure, energetic-tired, clearheaded-confused, composed-anxious. Summary
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scores were computed for two of six symptoms: depression and anxiety. High scores
indicate positive mood. The Brief Symptom Inventory (BSI) is a short form of the Symptom
Checklist 90 Revised and consists of 53 items that assess a feeling or thought. It is scored on
a 5 point scale from 0 (no such problem) to 4 (severe problem). It provides ratings of
psychological distress in nine symptom areas: somatization, obsessive-compulsive,
interpersonal sensitivity, depression, anxiety, hostility, phobic anxiety, paranoid ideation,
and psychoticism (Derogatis and Melisaratos, 1983). Summary scores were computed for
three of nine symptoms: somatization, depression and anxiety. High scores indicate great
psychological distress. The Pennebaker Inventory for Limbic Languidness (PILL) assesses
the frequency of occurrence of 54 common physical symptoms and sensations and appears
related to the construct of somatization or to the general tendency to perceive and endorse
physical symptoms. A total score is computed by summing all items. It has been reported to
have high internal consistency (alpha = 0.88) and adequate test-retest reliability (0.70 over
two months) (NIH, National Ambulatory Medical Care Survey, 1979). Recently it has been
used as a measure of hypervigilance in fibromyalgia patients (McDermid et al., 1996). These
patients demonstrated lower pressure pain thresholds and tolerances and higher scores on the
PILL compared to arthritis patients and pain-free controls. The State-Trait Anxiety Inventory
(STAI) contains 20 statements evaluating levels of state and trait anxiety (Spielberger et al.,
1983). The STAI is comprised of two forms, one measuring general propensity to
experience anxiety (Trait Anxiety) and the other measures the subject's anxiety level at the
time of questionnaire completion (State Anxiety). Summary scores for either State and Trait
Anxiety is computed by summing all items for each forms. Higher scores indicate greater
anxiety level. Each of these instruments is widely used in clinical research and has good
psychometric properties.
Blood pressure measurements
Resting systolic and diastolic blood pressures were assessed on the right arm with an
automatic blood pressure monitor (Dinamap). Five measures obtained at 2 minute intervals
after a 15 minute rest period were averaged to derive measures of resting systolic and
diastolic arterial blood pressure.
Genotyping
Two hundred two enrollees consented to genotyping. Genomic DNA was purified from 198
subjects using QIAamp™ 96 DNA Blood Kit (Qiagen, Valencia, CA, USA) and used for
5′exonuclease assay (Shi et al., 1999). The primer and probes were used as described in
(Belfer et al., 2004). The genotyping error rate was directly determined and was <0.005.
Genotype completion rate was 95%. The PHASE program (Stephens et al., 2001;Stephens
and Donnelly, 2003) was used for haplotypes reconstruction.
Statistical analyses
Distributions of phenotype scores in the sample were evaluated to assess normality. All
examined variables appeared to be distributed approximately normal with the exception of
the BSI scores. The distributions of the BSI variables were bimodal. For all BSI variables
examined, approximately one third of the individuals in the study answered every question
in the negative and hence received a score of 30. The remaining individuals had scores that
were approximately normally distributed between the values of 49 and 75. As there was no
acceptable way to transform these bimodal response variables to normality, these values
were reduce to a binary form and data were recorded as to whether or not each individual
had a score above 30.
Our primary analysis for each of our psychological and physiological traits was a regression
in which we compared the number of copies of each haplotype with the response variable.
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For our explanatory variables, we defined tij to be the number of copies of haplotype i
possessed by individual j. So, for example, if individual j was heterozygous with haplotypes
H1 and H2, we assumed t1j = 1, t2j = 1, and t3j = 0. Similarly, if individual j was
homozygous for haplotype H1, we assumed t1j = 2, t2j = 0, and t3j = 0.
We chose to parameterize the linear model as follows:
(1)
where, for the normal phenotypes, yj is the trait value for individual j. For the binary BSI
variables, these analyses were performed according to the analogous logistic model.
The mean trait values for each diplotype using the parameterization in Equation 1 are given
in Table 1. Note that, when all six parameters are allowed to vary, this model fits a separate
mean to each of the 6 diplotypes and, for the normal variables, this is merely a
reparameterization of the one-way ANOVA on the diplotypes. To determine which pairs of
diplotypes had significantly different mean trait values, we used Tukey's Honestly
Significant Difference post hoc test in the case of the normal variables. For the binary
variables, we used likelihood ratio tests with a Bonferroni correction for these comparisons.
In addition when examining the differences between the mean trait values for each pair of
diplotypes, we attempted to determine how each haplotype behaved in a copy or dose-effect
manner by comparing the trait values of individuals with 0, 1, and 2 copies of each
haplotype. As with the comparisons between diplotypes, these were assessed via an
ANOVAs with Tukey's HSD test for the normal variables and were assessed directly from
the regression as likelihood ratio tests with a Bonferroni correction for the BSI variables.
The main advantage in parameterizing the model as a regression (as shown in Equation 1)
rather than as an ANOVA is that the regression model allows more direct way to examine
interactions between the haplotypes. Of note is that haplotype H1 plays a different role in
this parameterization than the other two haplotypes. The mean trait value for H1/H1
individuals is given by a single parameter, γ1, which serves as a baseline value in this
parameterization of the model. We chose this parameterization because it permits
interactions (additivity, dominance, etc.) between H1 and the other haplotypes to be easily
tested (see below). A second aspect of this model is that departures from additivity between
the haplotypes are captured in the interaction parameters γ12, γ13, and γ23. When these are
all zero, we have a strictly additive model in which the mean heterozygous trait values fall
exactly midway between the mean homozygous trait values.
We assumed in our analyses that the default model should be an additive model, so we first
tested for interactions using an F-test (likelihood ratio test for the BSI variables) in which we
compared the fit of the full model given in Equation 1 to the additive model in which γ12,
γ13, and γ23 are constrained to be equal to zero. If this test showed insufficient evidence for
non-additivity, that is, if the full model did not show a significantly better fit to the data than
the additive model, we halted our analysis at this point.
For the variables that showed evidence of non-additivity, we continued with our analyses.
We used the Akaike Information Criterion (Akaike, 1974) to find the best fitting model of
the form shown in Equation 1. The form of this “best-fit” model depended upon the trait
being examined, but generally looked like Equation 1 with one or more of the γij parameters
set to zero.
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Once we had obtained the “best-fit” model, we investigated the relationship between those
pairs of variables that had an interaction term that was significantly different than zero. The
parameterization shown in Equation 1 is well suited for this type of testing. For example,
interactions between haplotypes H1 and H2 are captured in the parameter γ12, as can be seen
by comparing the mean trait values for H1/H1, H1/H2, and H2/H2 in Table 1. When γ12 = 0,
the relationship between H1 and H2 is additive. When γ12 = -γ2, H1 is dominant to H2.
When γ12 = γ2, H1 is recessive to H2. Overdominance and underdominance occur when |γ12|
> |γ2|. Thus, with this parameterization, relationships such as additivity, dominance,
recessiveness, and over/underdominance are hypotheses that can be expressed in terms of
the model's parameters and hence can be easily tested. The relationship that was of particular
interest to us was that of over/underdominance and we tested for this type of relationship
using a likelihood ratio test in which we compared the maximum obtainable likelihood
under the best-fit model with that under the constraint that |γ12| ≤ |γ2|.
Investigations of the relationship between haplotypes H1 and H3 proceeded with this model
analogously to the procedure for testing relationships between H1 and H2. Interactions
between H2 and H3 are less neatly summarized by the parameters in Equation 1. For those
comparisons, we reparameterized the model, exchanging the roles of H1 and H2 so that H2/
H2 individuals served as the baseline.
As a final note, this was a preliminary study with a small sample size (ultimately about 38
H1/H1, 50 H1/H2, 25 H1/H3, 25 H2/H2, 32 H2/H3 and 10 H3/H3 individuals, but these
numbers varied slightly depending upon which variable was being examined). Since our
intention was to gain insight, we were more concerned with Type II than Type I error.
Therefore, at each step where our protocol required us to proceed with follow-up testing
only if a previous test was significant, we set our criterion of significance at p ∼0.10.
EST database analysis
In order to examine if there is a significant difference in the expression of ADRB2 mRNA
driven by allelic combinations at the promoter region of the three identified haplotypes, we
analysed existing expressed sequence tag (EST) databases. Since sequencing of each EST
clone is a random non-selective process, and there are substantial numbers of EST
sequences in the NCBI EST data base, the frequency of gene-specific ESTs is a measure of
its RNA expression level (Bortoluzzi and Danieli, 1999). This approach has been used in
several studies to estimate the relative abundance of specific RNA transcripts (Lee et al.,
1995;Okubo et al., 1992;Comeron, 2004;Castillo-Davis et al., 2002), as well as it's tissue or
stage-specific levels (Lee et al., 1995;Comeron, 2004;Shen, He et al., 2005). It has also been
shown that the relative RNA expression values between SAGE, EST and microarray
databases are comparable (Comeron, 2004).
Computer analysis of all SNP combinations in the human EST database (dbEST release
030405, 6,053,112 - human entries) was performed using the BLAST program. Complete
nucleotide sequence of ADRB2 gene was analyzed (length - 2015 nucleotides, accession
number - NM_000024). We used a custom designed program, which was programmed in C
and contained a Bash shell script, to generate BLAST program output files. Our program
produces an output file (*.csv) in Excel format that contains a complete list of nucleotide
variation (SNPs) and their combinations for the selected gene in the EST database. We
restricted the analysis of nucleotide variations to known common SNPs with frequencies
>10%. Only hits with >95% of similarity over 100 nt to the original sequence were
considered. A Chi-Square analysis was used for statistical assessment of the EST data.
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From the initial 202 enrolled subjects that were genotyped, 181 (∼ 90%) completed the 3-
year observation period and 15 enrollees developed TMD. We investigated the relationship
of the incidence of TMD in our study population with different diplotypes by calculating the
relative risk of TMD onset. Since our sample sizes were small compared to the TMD
incidence levels, we calculated confidence intervals for our relative risks using Koopman's
method (Koopman, 1984).
Results
Common haplotypes of ADRB2
Genomic DNA from peripheral blood samples was genotyped for SNPs within the ADRB2
gene locus. Eight SNPs were chosen that display a high frequency of polymorphism in the
human population (> 20% prevalence), and form one haploblock (Belfer, et al., 2004) (Fig.
1). The first five examined SNPs (G-7127A, rs11958940, rs1432622, rs1432623 and
rs2400707) are located in the promoter region of the gene. The next three SNPs (rs1042713,
rs1042714 and rs1042717) are located within the coding region for gene. Variations
Arg16Gly (rs1042713) and Gln27Glu (rs1042714) are well-studied common nonsynonymous
polymorphisms. SNP Leu84Leu (rs1042714) is a synonymous polymorphism. The known
functional SNP Thr164Ile was also assessed, however none of the examine subjects
possessed the minor allele.
In agreement with previous reports (Belfer et al., 2004;Drysdale et al., 2000), three major
haplotypes were determined, representing 97.4% of all haplotypes observed in this study
(Fig. 1B). Only five subjects carried haplotypes that were different from the three major
ones. Each of these five haplotypes was different from one of the major haplotypes at only
one or two SNP position and was considered in subsequent analyses as one of the major
corresponding haplotypes.
Association of ADRB2 polymorphism with blood pressure and psychological traits
Descriptive statistics from the full 6-parameter (6 common diplotypes) regression model for
each response variable are presented in Figure 2. Of the ten trait values examined, three (BSI
anxiety, STAI state anxiety, and POMS elated-depressed) showed no associations and were
not examined further. We also analyzed the effect of haplotype copy number (i.e., dose-
effect) on the tested traits. We found a significant association of the number of copies of
haplotype H1 with both resting systolic and diastolic blood pressures, and an effect of
haplotype H2 on resting diastolic blood pressure (Fig. 3A). Subjects with no copies of H1
had significantly lower resting blood pressure than those who had one copy (Fig. 2A).
Consistent with this observation, subjects who carried two copies of H2 showed
significantly lower resting diastolic blood pressure than those who carried no copies of H1
(Fig. 2A). H1 heterozygotes, with either H2 or H3, displayed the highest systolic blood
pressures, and H1/H3 heterozygotes displayed the highest diastolic blood pressure, while H2
homozygotes and H2/H3 heterozygotes had the lowest systolic and diastolic blood pressures
(Fig.2A). Thus, our data suggest an overdominant relationship between H1 and H3 and
possibly between H1 and H2 haplotypes: subjects with one copy of H1 had higher systolic
and diastolic blood pressures than subjects homozygous for either haplotype (Fig. 3A).
The H2 haplotype was significantly associated with somatization scores (Fig. 3B). Subjects
bearing two copies of H2 had significantly higher levels of somatization (both PILL and BSI
scores) than subjects possessing only one or no copies of H2 (Fig. 3B). H2 homozygotes
displayed the highest somatization score among all diplotypes (Fig. 2B). H2 was also
significantly associated with trait anxiety: subjects with no H2 reported higher trait anxiety
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levels than those bearing one copy of H2 (Fig. 3B). Consistent with this result, homozygotes
for H1 and homozygotes for H3 had the highest trait anxiety scores, while H2 heterozygotes
had the lowest scores, although these results must be tempered by the fact that the overall
association between the ADRB2 haplotypes and this trait was weak (Fig. 2B, Table 2). H3
was strongly associated with the POMS composed-anxious score (lower scores correspond
to more negative characteristics) and BSI depression. H3 homozygotes had significantly
higher state-dependent anxiety (POMS composed-anxious), and lower BSI depression
scores (Fig.3C).
Haplotype interactions
Table 2 summarizes the findings from assessments of interactions between haplotypes. For
systolic blood pressure, diastolic blood pressure, and BSI depression scores a comparison
between the additive model and the full model, which included all possible interaction,
indicated that the model with interactions provided a better fit to the data. There was some
indication that this is also the case for somatization (PILL; P=0.1042), and the POMS
measure of “composed-anxious” (P=0.1133) scores.
Systolic and diastolic blood pressure variables had a best-fit to the model that included
significant interactions between H1 and H2 and between H1 and H3. Further analyses did
not support the hypothesis that H1 and H2 showed over/underdominance (P=0.341,
P=0.862) for either of the blood pressure phenotypes. However, the interaction between
haplotypes H1 and H3 was significant (P=0.045) for diastolic blood pressure and tend to
support an overdominance effect for systolic blood measure (P=0.082).
For BSI depression, the best-fit to model included a significant interaction between H1 and
H3. A likelihood ratio test for over/underdominance in the relationship between H1 and H3
gave a p-value of 0.044, supporting an overdominant relationship.
ADRB2 polymorphism and RNA expression
The vast majority of published studies that have examined ADRB2 polymorphism describe
associations with the nonsynonymous Arg16Gly (rs1042713) and Gln27Glu (rs1042714)
SNPs. It has been consistently observed that Arg16Gly polymorphism is associated with
agonist-induced internalization of the receptor (Small et al., 2003). Although several
phenotypes have been associated with Gln27Glu polymorphism, the functional effects of this
SNP remain unclear (Small et al., 2003). We hypothesized that since Gln27Glu
polymorphism is in strong linkage disequilibrium (LD) with SNPs in the promoter region
(rs11958940, rs14326222, rs14326223, rs2400707; Fig. 1) that a set of these SNPs defines
the efficiency of RNA transcription, and haplotype H1 codes for reduced efficiency of
transcription compared to H2 and H3.
To examine if there is a significant difference in the level of expression of ADRB2 mRNA
driven by allelic combinations at the promoter region of three haplotypes, we estimated the
relative expression level of ADRB2 mRNAs on the basis of the relative abundance of ESTs,
as described by Castilo-Davis and coworkers (2002). We assigned each EST in available
EST libraries to one of the three identified haplotypes based on their EST sequence (Table
3). If each haplotype codes at similar transcription efficiencies, we would expect the
haplotype-specific ESTs to appear in the databases in proportion to the population haplotype
frequencies, whereas, if transcription efficiencies vary between the different haplotypes, we
would expect those haplotypes that produce more transcripts to be over-represented.
Fifty-three ADRB2 EST were found. Twenty-four of these had a sequence in the 5′region of
the gene that permitted the identification of the corresponding haplotype. Five ESTs
corresponded to H1, 8 ESTs corresponded to H2, and 11 ESTs corresponded to H3 (Table
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3). We compared haplotype-specific EST frequencies with the haplotypes frequencies in our
cohort (Fig. 1), as well as haplotype frequencies reported by others (Belfer et al., 2004). The
distribution of EST frequencies was statistically different from the distribution of haplotype
frequencies in both cohorts (χ2 analysis; P's <0.05). After normalization to haplotype
frequencies in human population, the amounts of H2- and H3-specific ESTs relative to H1
were 1.8 and 4.4 respectively (Table 3), which suggests that H1 codes for a lower efficiency
of transcription compared to H2 and H3. Since the allelic combination of H1 in the promoter
region of the gene and Gln27Glu SNPs is opposite to the allelic combination associated with
H2 and H3 (haplotype AAAGG versus TGGAC for rs11958940, rs14326222, rs14326223,
and rs2400707, Gln27Glu, respectively; Fig. 1) our data suggest that H1 codes for a lower
efficiency of transcription while H2 and H3 code for high efficiency of transcription.
ADRB2 haplotypes and risk of TMD
Next, we determined the clinical significance of ADRB2 genetic variants by examining
whether ADRB2 polymorphism is related to the incidence of TMD onset. We predicted that
since ADRB2 genotype is associated with somatization, depression, trait anxiety and low
blood pressure, which are phenotypic characteristics commonly associated with chronic pain
conditions, these genotypes should also be associated with TMD development. Because
none of the three major haplotypes showed a simple relationship with all of these
psychological characteristics or blood pressure, but instead showed a complicated interplay
of associations, we suggest that there are complex interactions between different haplotypes
and associated molecular properties of the corresponding receptor variants. We hypothesised
that specific combinations of receptor variants contribute to the development of TMD more
than others.
Based on the analysis of the ADRB2 EST databases, as well as previously published
literature (Small et al., 2003), we suggest there are two primary functional sites within the
human ADRB2 gene locus: one that influences the level of receptor expression and one that
influences that ability of the receptor to internalize in response to agonist stimulation. Based
on these assumptions, haplotypes were subdivided for those coding for lower ADRB2
expression (H1 haplotypes, low ADRB2 expression, “Lo”, Table 4A), and those that code for
high ADRB2 expression (i.e., H2 and H3 haplotypes, high ADRB2 expression, “Hi”, Table
4A). Similarly, H1 and H3 haplotypes, coding for Gly16 associated with efficient
internalization of the receptor, were clustered into group “I” and H2 coding for Arg16 was
identified as group “N” (Table 4B).
Of 181 subjects followed over the three year observational time period, 15 were diagnosed
with first-onset TMD, yielding an overall incidence of 8.3%. TMD incidence was highest
among the 25 H2/H2 homozygotes (5/25 = 20% (0.200), Table 4). The lowest TMD
incidence was among H1/H2 and/or H1/H3 heterozygotes. Although the “Hi/Lo” reference
group of H1 heterozygotes represented almost half of the initially tested cohort ((n=76),
Table 4A) only one TMD case was observed in this group, yielding a TMD incidence of
1.3%. Compared with the reference group of “Hi/Lo” H1 heterozygotes, there was a
significantly elevated risk of developing TMD for “Lo” homozygotes (relative risk [RR] =
8.0, 95% confidence interval [CI] = 1.2 – 52.2 and 99%CI = 0.815-79.7) and a significantly
elevated risk for the “Hi” homozygotes (RR=11.3, 95%CI = 1.95-67.9, and 99%CI =
1.38-102.1). Grouping subjects based on receptor internalization characteristics yielded
lower RRs. Specifically, comparing the N/N group with the heterozygotes I/N group as a
reference group, revealed an RR=3.32, with a 95% CI = 1.08-9.83, and 99%CI = 0.794-13.2.
These results strongly suggest a significant influence of receptor expression level on risk of
TMD development. The lowest TMD incidence rate of the subjects caring one copy of H1
(i.e., heterozygous for H1-H2 or H1-H3, “Hi/Lo” group) is consistent with the evidence for
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an overdominance effect of H1, when coupled with either H2 or H3 (Table 2), more positive
psychological characteristics and higher resting blood pressure for Hi/Lo heterozygotes (Fig.
2 and 3), which are characteristics that appear to protect from the development of TMD.
Discussion
A heuristic model of functional variants of ADRB2
Our conceptual model of the complex interplay of associations between ADRB2 haplotypes,
human psychological traits and blood pressure are presented in Fig.4. We analyzed our
association data taking into account the following reported properties of the receptor
stimulation: i). a high level of receptor activity has been reported to produce antidepressant-
-like effects in rodents (Zhang, Huang, and O'Donnell, 2003); ii). reductions in the density
of β-adrenergic receptors are associated with depression- and anxiety- related clinical
conditions (Magliozzi et al.;Maddock et al.; Mann et al.) and the density of ADRB2 is
negatively correlated with anxiety and depression assessed with unidirectional POMS
questionnaire (Yu, Dimsdale, and Mills, 1999); iii). chronic stimulation of ADRB2 enhances
epinephrine-mediated physiological arousal and increases somatic awareness across multiple
systems (e.g., gastrointestinal, cardiorespiratory, etc.) (Kopin, 1984;Easton and Sherman,
1976;Lader, 1988); iv). stimulation of ADRB2 lead to decreased blood pressure (Brodde and
Michel, 1992;Iaccarino et al., 2002;Gratze et al., 1999;Snapir et al., 2003). Furthermore, we
considered haplotype-specific differences in the ability of receptor to be internalized in
response to agonist stimulation: H1 and H3 haplotypes code for a rapid internalization of
receptor, as these two haplotypes carry the G allele at SNP rs1042713 (Arg16Gly), which
codes for Gly16 (Fig. 1) (Small et al., 2003). Finally, we took into account haplotype-
specific level of receptor expression, assuming that H1 codes for the lowest amount of
ADRB2 RNA and H3 codes for the highest amount of ADRB2 RNA (table 3). Based on
these assumptions we propose a model that explains how different haplotypes produce
different phenotypes (Fig. 4).
In the resting physiological state, H1 homozygotes express several times fewer receptors
than either H2 or H3 homozygous (Fig. 4A). Chronically diminished ADRB2 function in the
CNS, as we proposed for H1 homozygotes, would produce psychological traits such as
depression and anxiety, which has been observed in some patients treated with non-selective
ADRB receptor blockers (Thiessen et al., 1990). In contrast, H2 codes for higher receptor
expression (Table 3) coupled with low efficiency of agonist-induced receptor internalization
(Small et al., 2003). Chronically enhanced ADRB2 function, as we proposed for H2
homozygotes, would display psychological characteristics of physiological arousal and
enhanced awareness of bodily functions (i.e., somatization, Fig 2B, 3B) evoked by
stimulation of central ADRB2 and a reduction in arterial blood pressure by stimulation
ADRB2 on peripheral blood vessels (Fig.2A, 3A). In agreement with these observations, H2
demonstrated a protective role against elevated trait anxiety because subjects without H2
reported significantly higher trait anxiety scores, although the lowest trait anxiety scores
were reported by subjects with one copy of H2, rather then with two copies of H2 (Fig. 2B
and 3B).
Endogenous stimulants, such as epinephrine released from the adrenal glands in response to
a stressful situation, should lead to a rapid internalization of receptor variants H1 and H3.
For the H3 homozygotes, but not H1 homozygotes, this would lead to a significant reduction
in receptor density producing a stress-evoked state-dependent anxiety (Fig. 2C and 3C; Fig.
4B), as H3 expresses the highest level of ADRB2 (Table 3). Furthermore, H3 homozygotes
reported the lowest level of BSI depression (BSI) (Fig. 2C and 3C). This is in agreement
with the evidence that H3 codes for the highest level ADRB2 expression (Table 3), which
mediates an anti-depression effect (Gorman and Dunn, 1993). On the other hand, we
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proposed that the efficient epinephrine-dependent internalization of the receptor, which
should be associated with H3 homozygotes, will lead to highly dynamic changes in receptor
density resulting in high psychological reactivity and low depression scores. Based on this
model, we propose that the relative rank order of ADRB2 receptor function in response to
agonist stimulation is the following: H2 (high expression/low rate of internalization) similar
to H3 (high expression/high rate of internalization), both of which are greater than H1 (low
expression/ high rate of internalization).
We observed some inconsistency in association pattern of ADRB2 polymorphism with
different measures of depression and anxiety. Specifically, the derived measure of
depression from the POMS questionnaire failed to show an association with ADRB2, while
BSI depression score did. Similarly, different measures of anxiety were associated with
different haplotypes in our study. We suggest that this reflects differences in the parameters
of anxiety and depression measured by different questionnaires. For example, the STAI
Trait Anxiety scale measures trait or chronic levels of perceived anxiety and based on our
model is negatively correlated with the haplotype that produce and maintain high levels of
ADRB2 expression (i.e., H2). Anxiety assessed with the POMS scale assesses the level of
anxiety experienced in the ‘here and now” (Yu et al., 1999), and based on our model, should
be dynamically associated with the efficiency of agonist-induced receptor internalization
that occurs in response to acutely stressful environmental events (i.e., H3). STAI State
anxiety and BSI anxiety measures may tap into a combination of these two anxiety
constructs and that is why these measures were not associated significantly with either
haplotype. Consistent with our findings, it has been reported that increased POMS measures
of anxiety, but not STAI Anxiety measures, are highly associated with the down-regulation
of ADRB on human lymphocytes (Yu et al., 1999).
Our heuristic model (Fig. 4) demonstrates why it is necessary to consider haplotypes rather
than single SNPs. Each haplotype codes for two basic receptor properties - the level of
expression and the internalization responses produced by agonist stimulation. Both of these
properties influence physiological responses and phenotypes associated with ADRB2.
Consistent with our model, Drysdale and coworkers (2000) reported a complex relationship
between the three major ADRB2 haplotypes and bronchodilator responses to a ADRB2
agonist. Mean responses was significantly related to the haplotype pairs (P = 0.007) but not
to individual SNPs.
We would like to stress that the proposed heuristic model does not explain the entire
complexity of ADRB2 biology and its role in chronic pain conditions and related
phenotypes. There are multiple mechanisms that contribute to ADRB2 regulation, including
the bioavailability of the agonist, posphorylation, endocytosis and recycling of the receptor,
and receptor expression and translation. Each process is regulated by different pathways and
depends on the biological activities of a complex gene network. Future studies designed to
investigate the interaction between genetic variants of ADRB2 and the genetic variants of
other genes are required that will more comprehensively elucidate our understanding of
individual variations in ADRB2-mediated phenotypes.
ADRB2 polymorphism and resting blood pressure
Although several studies have examined the association between resting arterial blood
pressure and ADRB2 polymorphism, the published results vary and are often difficult to
interpret. The associations between resting blood pressure and the three major ADRB2
haplotypes observed in our study reveal a complex pattern of associations, which can be
explained by a combination of putative effects: i). haplotype-specific differences in the
amount of expressed receptor; ii). haplotype-specific differences in the ability of receptor to
be internalized in response to agonist stimulation; iii). an overdominance effect associated
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with H1; and iv). tissue-specific differences in ADRB2 mediated vasodilatory responses,
such that stimulation of CNS ADRB2 results in elevations in arterial blood pressure while
stimulation of peripheral ADRB2 results in a reduction in arterial blood pressure.
It is well know that the stimulation of vascular ADRB2 produces peripheral vasodilation,
decreases peripheral vascular resistance, and lowers arterial blood pressure (Brodde and
Michel, 1992;Iaccarino et al., 2002;Gratze et al., 1999;Snapir et al., 2003). Thus, it is
generally accepted that decreased peripheral vascular resistance and lower resting arterial
blood pressure results when relatively higher amounts of ADRB2s are expressed on
peripheral blood vessels. In contrast, stimulation of ADRB2 in the CNS produces an
increase in peripheral vascular resistance and arterial blood pressure (Routledge and
Marsden, 1987;Ward-Routledge et al., 1988). Thus, tissue specific regulation of receptor
expression, which occurs in a haplotype specific manner, may differentially influence
resting arterial blood pressure.
A substantial number of publications have shown that the magnitude and direction of
agonist-induced peripheral vasodilation is associated with ADRB2 polymorphisms. The
intravenous infusion of epinephrine produces effects on blood pressure in a manner that
depends on the ADRB2 genotype (Snapir, et al., 2003). Individuals with at least one A allele
at SNP rs1042713 (Arg16Gly), which codes for Arg16 and is a specific marker for H2, show
reduced diastolic blood pressure in response to a graded epinephrine infusion. In contrast,
individuals carrying the Glu27 allele, which is specific to H1 (Bray et al., 2000) (low
expression/rapid internalization) or Gly16 (Kotanko et al., 1997), which is specific for both
H1 (low expression) and H3 (rapid internalization), have been associated with essential
hypertension and diminished peripheral vasodilatory capacity in response to ADRB2
stimulation (Gratze et al., 1999;Hoit et al., 2000).
Our findings are in agreement with these reports and we propose that variations in resting
arterial blood pressure can be explained by the effects of ADRB2 polymorphism on receptor
expression and/or receptor internalization. For example, resting arterial diastolic blood
pressure is associated with the number of copies of H2 (Fig. 2A). H2 homozygotes (high
expression/slow internalization) had the lowest resting diastolic pressure and subjects
without a H2 haplotype (subjects with combinations of H1 and H3, rapid receptor
internalization) had the greatest resting diastolic pressures (Fig.2A, 3A). An even stronger
effect was observed for H1 (Fig. 2A, 3A). Subjects with no H1 (subjects with combinations
of H2 and H3, high receptor expression) had the lowest systolic and diastolic blood pressure
(Fig. 2A, 3A). Although homozygotes for H1 had higher resting arterial blood pressure, the
highest resting arterial systolic and diastolic blood pressures were seen with H1-H2 and H1-
H3 heterozygotes (Fig. 3A), suggesting a H1 overdominance (Table 2). It is noteworthy that
these same individuals were less likely to develop TMD (Table 4), which is consistent with
the substantial literature that pain sensitivity and the risk of developing chronic
musculoskeletal conditions is inversely related to resting arterial blood pressure (Hagen et
al., 2005;Bruehl and Chung, 2004;Fillingim, Maixner, et al., 1998;Fillingim and Maixner,
1996;Maixner et al., 1997;Pfleeger et al., 1997;Maixner, 1991;Randich and Maixner,
1984;Sheps et al., 1992).
Haplotype-dependent ADRB2 expression
Our analysis of EST databases suggests that H1 codes for a lower amount of RNA
expression compared to H2 and H3. The outcomes of our association study, and known
effects of genetic variations in ADRB2 on various physiological functions such as blood
pressure (Bray et al., 2000) and airway resistance (Tattersfield and Hall, 2004), support this
conclusion. Two cell biology-based studies that examined the relationship between ADRB2
expression and common polymorphisms did not provide congruent results (McGraw et al.,
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2000), which may be due to tissue specific effects on haplotype expression. Future cell
culture studies are required to accurately assess haplotype-specific expression in different
tissue-specific cell lines, which will more directly test our proposed model (see below) that
H1 codes for a lower level of expression of the receptor compared to H2 and H3,
particularly in the CNS.
Overdominance associated with ADRB2 H1 haplotype
An overdominance of H1 over H2 and H3 is another feature of ADRB2 genetics that
complicates the interpretation of association studies. Heterozygotes for H1-H2 and H1-H3
show the highest level of resting arterial blood pressure (Fig. 2A). Although the H1-H2 and
H1-H3 heterozygotes represented almost half of the initially tested cohort, only one TMD
case was observed in this group, yielding a significantly elevated risk of developing TMD
for both “Lo” and “Hi” homozygotes and suggests that the presence of one copy of H1 is
protective against TMD onset. An overdominance was further confirmed by a linear
statistical model that investigated the interactions between haplotypes. The best-fit model
for resting blood pressure revealed interactions between the H1 with H2 and H3, but only
the H1-H3 interaction revealed a significant overdominance, which is likely due to the
limited sample size. The H1-H3 interaction also showed overdominance when associated
with BSI assessed depression phenotype (Table 2): H1-H3 heterozygotes showed the highest
BSI assessed depression score while H3 homozygotes showed the lowest BSI depression
score (Fig. 3). Consistent with our findings, other investigators have observed non-linear
relationships between ADRB2 haplotype dosage and corresponding mean values of assessed
phenotypes (Drysdale et al., 2002).
An overdominance has been described in crop genetics (Syed and Chen, 2004) and there is
accumulating evidence that overdominance is a common occurrence in humans, with
heterozygotes expressing phenotypic values that are either substantially above or below both
homozygotes. While the mechanism(s) underlying the phenomenon of overdominance is
poorly understood, we suggest that the overdominance effect of H1 haplotype, when
combined with H2 and H3, on blood pressure and psychological associations results from
the integration of opposite effects associated with central vs peripheral ADRB2 activation
(Brodde and Michel, 1992;Iaccarino, et al., 2002;Gratze, et al., 1999;Snapir, et al.,
2003;Routledge and Marsden, 1987;Ward-Routledge et al., 1988). Another possible
explanation is that the dose-effects evoked by a ADRB2 stimulant produces an inverted U-
shaped dose-response curve. U-shaped responses are commonly seen under normal
physiological conditions. For example, U-shaped behavioral responses are seen in response
to graded stimulation of the locus coeruleus, a region of the brain important in attention,
autonomic function, arousal, anxiety, and goal directed behaviors (Aston-Jones et al., 1999).
The third possibility is tissue specific effects on haplotype expression. In fact, it has been
shown in a recent study analyzing more than 140 polymorphisms involved in the regulation
of 107 genes that single-locus tissue-specific overdominance is very common and may
represent a selective mechanism for the maintenance of cis-regulatory variation (Rockman
and Wray, 2002). Thus, additional studies are required to identify the mechanism(s) of the
observed overdominance effect.
Limitations associated with this study
We recognized that our study was conducted on a limited number of subjects. As a
consequence, we did not consider each genetic variant independently, but instead haplotype
groups based on their likely biological properties: receptor expression level and
internalization efficiency. The grouping of haplotypes supports the suggestion that receptor
expression level strongly influences the risk of TMD development with Lo/Hi heterozygotes
are protected from developing TMD. However, it is possible that relative risk of
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development of TMD will be largely different among the subjects with different diplotypes
once a larger cohort is examined.
Clinical relevance of the observed associations with ADRB2 haplotypes
Our results are of considerable clinical significance and are the first to demonstrate an
association between a genetic polymorphism that correlates with psychological traits, resting
blood pressure, and the risk for developing a common chronic pain condition. The observed
genetic risk associated with ADRB2 polymorphism is substantially greater than that
associated with other risk factors such as estrogen exposure, history of chronic pain at other
body sites (John et alk., 2003;Von Korff et al., 1993), and genetic variations in the gene that
codes for COMT (Diatchenko et al., 2005). The clinical relevance of these findings is best
quantified by the measure of population attributable risk for being homozygous for either
high or low expression of ADRB2, which was 82% in this cohort of women, indicating that
more than eight of ten myogenous TMD cases can be predicted by these ADRB2 haplotypes.
Individuals with relatively high ADRB2 function (H2 and H3) had a high likelihood of
developing TMD (Table5). H2 homozygotes showed the highest TMD incidence rate
(0.200). These subjects showed high somatization score and low blood pressure, which are
factors that appear to influence the development chronic musculoskeletal pain conditions
(Maixner et al., 1997;Bruehl and Chung, 2004;Macfarlane et al., 2004). H2-H3
heterozygotes and H3 homozygotes, where ADRB2 function should be slightly diminished,
showed TMD incidence rates of 0.125 and 0.100 respectively, which was still higher than
the average TMD incidence rate of 0.083. The homozygotes for low ADRB2 function also
show increased risk for TMD development with incidence rate of 0.105. These findings
suggest that subjects with either high or low ADRB2 receptor activity are at risk of
developing a chronic pain condition via different etiological pathways. H1 heterozygotes,
those who carry one haplotype copy that codes for high ADRB2 expression (H2 or H3) and
one copy of H1 that codes for low ADRB2 expression and rapid internalization were
protected from the development of TMD. Only one subject who was H1-H2 heterozygote
developed TMD, even though almost half of all the variants observed in our cohort were
H1-H2 or H1-H3 heterozygotes (Table 4). Thus, our data suggest that either positive or
negative imbalances in ADRB2 function increase the vulnerability to TMD. Collectively 14
of 15 TMD (93%) patients were associated with a putative hyperfunction (10/15) or
hypofunction of (4/15) of ADRB2 (Table 4).
Our findings also have potentially important treatment implications. If ADRB2
hyperfunction contributes to TMD, then a relatively high percentage of these patients (∼
60-70%) should respond to treatment with an ADRB2 antagonist, like propranolol. In
contrast, approximately 25 to 30% of TMD cases should have a hypofunction of ADRB2
(H1/H1) and should not respond to treatment with ADRB2 antagonist. In fact, treatment of
this group with such an agent may actually worsen their signs and symptoms. Thus, it may
be possible to predict treatment outcomes to ADRB2 blockade by determining the specific
haplotype profile for patients with TMD and related disorders.
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(a) Schematic diagram of ADRB2 genomic organization, SNP positions and
distribution percentages. The human ADRB2 is an intronless gene that spans ∼5,500 kb on
chromosome 5q31-32. ADRB2 transcript codes for two independent peptides showed as
break blocks: β2 adrenergic receptor protein and β2 adrenergic receptors upstream protein
(BUP) that inhibits receptor translation (Parola and Kobilka, 1994). (b) Estimated
frequencies of the ADRB2 haplotypes. The sequence of alleles in each haplotype reflects
the order of occurrence from 5′ to 3′ in the ADRB2 gene locus (SNPs: G-7127A,
rs11958940, rs1432622, rs1432623, rs2400707, rs1042713, rs1042714 and rs1042717,
respectively).
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Figure 2. Psychological scores and resting arterial blood pressure categorized by six major
ADRB2 diplotypes
The major effects of six major ADRB2 diplotypes are presented. The following diplotypes
are shown: homozygotes for H1 (1,1), homozygotes for H2 (2,2), homozygotes for H3 (3,3),
heterozygotes H1-H2 (1,2), H1-H3 (1,3), and H2-H3 (2,3). Each value represents the mean
of each variable with associated SEM. Greater positive values for PILL, BSI and Trait
Anxiety scores reflect more negative psychological characteristics. The greater values for
measured obtained from the POMS scale reflect more positive psychological characteristics:
composed. PILL, STAI and POMS scores were measured in relative unites, blood pressure
was measured in mm of mercury (mmHg), BSI depression and somatization presented as
percent of subjects that show trait (subjects, scored at 30 and corresponded to individuals
that answered all questions negatively, were treated as a group that showed no signs of
depression or somatization). ***P < 0.01, **P < 0.05 and *P < 0.1 different from the
indicated groups.
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Figure 3. The effect of ADRB2 haplotypes on psychological scores and resting arterial blood
pressure
The major effects of the number of copies of haplotype 1 (A), haplotype 2 (B) or haplotype
3 (C) are presented. The following haplotype dose-effects are shown: no corresponding
haplotype (0), one copy (1) or two copies (2) of the corresponding haplotype. Each value
represents the mean of each variable with associated SEM. Greater positive values for PILL,
BSI and Trait Anxiety scores reflect more negative psychological characteristics. The
greater values for measures obtained from the POMS scale reflect more positive
psychological characteristics: composed. PILL, STAI and POMS scores were measured in
relative unites, blood pressure was measured in mm of mercury (mmHg), BSI depression
and somatization presented as percent of subjects that show trait (subjects, scored at 30 and
corresponded to individuals that answered all questions negatively, were treated as a group
that showed no sings of depression or somatization). ***P < 0.01, **P < 0.05 and *P < 0.1
different from the indicated groups.
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Figure 4. Proposed functional variants of ADRB2 corresponding to the three major haplotypes
Putative haplotype-specific expression of ADRB2 on the postsynaptic membrane of CNS
neurons at (A) resting state and (B) following stimulation with an agonist. In the periphery,
epinephrine is released from adrenal glands and binds peripheral ADRB2, for example,
smooth muscle.
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Table 1
Haplotypes interactions: Mean trait values
Diplotype Mean trait value
H1/H1 γ1
H1/H2 γ1 + γ2 + γ12
H1/H3 γ1 + γ3 + γ13
H2/H2 γ1 + 2γ2
H2/H3 γ1 + γ2 + γ3 + γ23
H3/H3 γ1 + 2γ3
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Table 3
Relative EST abundance
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